The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
Clinical diagnosis of dry AMD.
Ability to understand and give informed consent.
Adult male or female >55 years of age.
Medically suitable to undergo vitrectomy and subretinal injection (>60% on Karnofsky scale).
Allergy or hypersensitivity to dilation drops or fluorescein.
Active major medical conditions limiting ability to participate in the study.
Active malignancy or treatment with chemotherapy.
Systemic immunosuppressant therapy within past six months.
Luxa Biotechnology, LLC
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Eye Institute (NEI)
Collaborator
Regenerative Research Foundation
Collaborator
California Institute for Regenerative Medicine (CIRM)
Collaborator